Trial Profile
Randomized Phase II Study of Gemcitabine (GEM) Versus GEM+TS-1 for Advanced Pancreatic Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Oct 2017
Price :
$35
*
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Gemcitabine
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 18 Jan 2014 Pooled results for prognostic factors from GEST, GEMSAP, and JACCRO PC-01 presented at the 2014 Gastrointestinal Cancers Symposium.
- 01 May 2012 Primary endpoint 'Objective-clinical-response-rate' has been met according to results published in Cancer Chemotherapy and Pharmacology.
- 01 May 2012 Results published in Cancer Chemotherapy and Pharmacology.